SCHEMBL20914077

SCHEMBL20914077

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 2/20 0.37
▸ TNKS2 Q9H2K2 2/20 0.37
▸ PARP2 Q9UGN5 1/20 0.37
▸ HTT P42858 3/20 0.36
▸ MAT2A P31153 1/20 0.35
▸ F2RL3 Q96RI0 2/20 0.35
▸ HPGD P15428 6/20 0.33
▸ MAPT P10636 5/20 0.33
▸ MEN1 O00255 4/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ HSD17B10 Q99714 4/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ LMNA P02545 2/20 0.33
▸ APAF1 O14727 1/20 0.33
▸ TSHR P16473 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837249 0.91 TNKS (0.37) TNKSTNKS2PARP2HTTMAT2A
SCHEMBL20913913 0.91 KCNA5 (0.38) TNKSTNKS2PARP2F2RL3HPGD
SCHEMBL20914221 0.89 HTR3A (0.31) MEN1KMT2ATSHRCYP1A2CYP2C9
SCHEMBL20836948 0.89 TNKS (0.35) TNKSTNKS2PARP2HTTMAT2A
SCHEMBL20914035 0.89 MAT2A (0.34) HTTMAT2AHPGDMAPTMEN1
SCHEMBL20914059 0.88 MAT2A (0.33) HTTMAT2AHPGDMAPTMEN1
SCHEMBL20931219 0.88 TNKS (0.40) TNKSTNKS2PARP2F2RL3HPGD
SCHEMBL20837038 0.88 ADORA2A (0.34) HTTMAT2AF2RL3MEN1KMT2A
SCHEMBL20913968 0.88 KDM4E (0.34) MAT2AHPGDMAPTMEN1KMT2A
SCHEMBL20914415 0.88 TNKS (0.39) TNKSTNKS2PARP2MAT2AF2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback